Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
NCT ID: NCT00255463
Last Updated: 2009-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
185 participants
INTERVENTIONAL
2004-01-31
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
NCT00077025
Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00049062
Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer
NCT00066378
A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
NCT00252811
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
NCT00206414
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anastrazole
Gefitinib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must post menopausal women who in the opinion of investigator would be likely to benefit from endocrine therapy. Postmenopausal patients are defined as:
* Natural menopause with last menses \> 1 year ago,
* Radiation induced oophorectomy with last menses \> 1 year ago,
* Serum FSH and LH levels clearly in the postmenopausal range for the institution.
* Bilateral oophorectomy
Exclusion Criteria
* Hormonal treatment within the last 2 weeks, previous hormonal treatment for invasive cancer
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca Iressa Medical Sciences Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Brno, , Czechia
Research Site
Chomutov, , Czechia
Research Site
Ostrava, , Czechia
Research Site
Ostrava - Poruba, , Czechia
Research Site
Prague, , Czechia
Research Site
Clermont-Ferrand, , France
Research Site
Montpellier, , France
Research Site
Tours, , France
Research Site
Villejuif, , France
Research Site
Budapest, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Kecskemét, , Hungary
Research Site
Coimbra, , Portugal
Research Site
Funchal, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Santiago de Compostela, A Coruña, Spain
Research Site
Jaén, Jaén, Spain
Research Site
Seville, Sevilla, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Zaragoza, Zaragoza, Spain
Research Site
A Coruña, , Spain
Research Site
Gothenburg, , Sweden
Research Site
Mölndal, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Chelmsford, Essex, United Kingdom
Research Site
Bournemouth, , United Kingdom
Research Site
Croydon, , United Kingdom
Research Site
Dundee, , United Kingdom
Research Site
Leeds, , United Kingdom
Research Site
Liverpool, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Newcastle upon Tyne, , United Kingdom
Research Site
Poole, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D7913C00223
Identifier Type: -
Identifier Source: secondary_id
1839IL/0223
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.